Unlocking the Potential of ELL2P1 as a Drug Target for RNA polymerase II and Long Non-Coding RNAs

Target Name: ELL2P1

NCBI ID: G646270

ELL2P1

Other Name(s): elongation factor for RNA polymerase II 2 pseudogene 1 | Elongation factor for RNA polymerase II 2 pseudogene 1

Unlocking the Potential of ELL2P1 as a Drug Target for RNA polymerase II and Long Non-Coding RNAs

Introduction

RNA polymerase II (RNA polymerase II, RNA-II) is a key enzyme in the process of gene expression, responsible for creating long non-coding RNAs (lncRNAs) as well as coding proteins. The RNA-II enzyme is composed of several subunits , including the long elongation factor LL2P1, which is essential for its function. The purpose of this article is to discuss the potential of LL2P1 as a drug target and its implications for the treatment of various diseases.

LL2P1: The Long Extension Factor for RNA-II

LL2P1 is a protein that belongs to the nucleotide-binding oligomerization domain (NBO domain) family. It is located at the base conserved 3'-end of RNA-II subunit alpha 2 and is responsible for the long extension of the 3'- end of RNA-II subunits. LL2P1 functions by binding to specific regions on the 3'-end of RNA-II subunits and extending the 3'-end by a specific sequence of nucleotides.

LL2P1 has been shown to play a critical role in regulating the activity of RNA-II and is required for its full function.LL2P1-deficient mice have been shown to have reduced levels of RNA-II and are resistant to the effects of RNA-II inhibitors. Furthermore, LL2P1 has been implicated in various diseases, including cancer, neurodegenerative diseases, and developmental disorders.

Drug Targeting LL2P1

The potential of LL2P1 as a drug target is high due to its unique mechanism of action and its involvement in various diseases. One of the main advantages of LL2P1 is its high degree of conservatism, which ensures that any drug developed to target LL2P1 would be unlikely to have off-target effects.

LL2P1 has been shown to be a good candidate for small molecule inhibitors. Studies have shown that inhibitors can reduce the activity of LL2P1 and increase the levels of RNA-II in cells. These inhibitors can also interact with LL2P1 and prevent it from binding to the 3'-end of RNA-II subunits, leading to the formation of a stable complex that is resistant to disruption by inhibitors.

Another approach to targeting LL2P1 is to use RNA-II depolymerizing agents, which can remove the long non-coding RNAs produced by LL2P1 and reverse the effects of inhibitors. This approach is useful for studying the mechanisms of LL2P1 inhibitors and their efficacy in treating diseases associated with LL2P1.

LL2P1 as a Biomarker

The expression of LL2P1 is regulated by various factors, including DNA binding, RNA binding, and protein-protein interactions. Therefore, the expression of LL2P1 can be used as a biomarker to study the effects of drugs on LL2P1 function.

LL2P1 has been shown to be a good biomarker for tracking the effects of RNA-II inhibitors on cancer cells. In cancer cells, LL2P1 is overexpressed, which can lead to the formation of long non-coding RNAs, thereby contributing to the development and progression of cancer. In contrast, inhibitors of LL2P1 have been shown to reduce the production of long non-coding RNAs and improve the sensitivity of cancer cells to inhibitors.

LL2P1 has also been used as a biomarker for tracking the effects of neurodegenerative diseases. In neurodegenerative diseases, LL2P1 is often overexpressed and forms long non-coding RNAs that are involved in the development and progression of the disease. In contrast, inhibitors of LL2P1 have been shown to reduce the production of long non-coding RNAs and improve the sensitivity of neurodegenerative disease

Protein Name: Elongation Factor For RNA Polymerase II 2 Pseudogene 1

The "ELL2P1 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about ELL2P1 comprehensively, including but not limited to:
•   general information;
•   protein structure and compound binding;
•   protein biological mechanisms;
•   its importance;
•   the target screening and validation;
•   expression level;
•   disease relevance;
•   drug resistance;
•   related combination drugs;
•   pharmacochemistry experiments;
•   related patent analysis;
•   advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai

More Common Targets